CV Sciences announces category expansion with new TCM immune formula sans CBD

July 29, 2020

CV Sciences Inc. has announced a strategic expansion of its product line to include non-CBD condition-specific dietary supplements.

CV Sciences Inc. (San Diego, CA) has announced a strategic expansion of its product line to include non-CBD condition-specific dietary supplements. The first to launch is CV Acute, which is a clinically researched, wide spectrum, proprietary plant-based formula that supports immune and respiratory health. The new product integrates a time-tested Traditional Chinese Medicine (TCM) herbal formula with modern analytical chemistry and extraction techniques.

“I was assigned to establish the Department of Defense Global Emerging Infections Surveillance Program in Southeast Asia in the early 2000's, helping manage both the SARS and Bird Flu outbreaks for the U.S. military. There I observed the tremendous value in combining traditional herbs with modern diagnosis and treatment,” said Michael D. Lewis, MD, MPH, Colonel (Retired), U.S. Army, and CV Sciences medical advisor, in a press release. ““TCM herbs have powerful anti-viral and anti-inflammatory activity without side-effects [often] associated with drugs. The herbs in CV Acute have been shown to be safe and effective alone or when added to modern medical treatment of viral and bacterial infections.”

“Our launch of CV Acute represents a strategic category expansion, and a natural evolution of CV Sciences’ positioning as a leading health and wellness company,” explained Joseph Dowling, chief executive officer of CV Sciences, in a press release. “CV Acute is considered a valuable botanical formula to maintain immune and respiratory health at times when protection is needed the most – including the uncertain times of the 2020/2021 flu season. This is particularly important as many retailers have not been able to offer CBD products, which have also demonstrated immune system support.”

He adds, “We considered adding CBD to the formula, however our goal is to make CV Acute broadly available to consumers through all retail channels at an affordable price so they can have easy access to the immune and respiratory health benefits this formula has demonstrated to provide. We view PlusCBD as a companion product to CV Acute because PlusCBD provides maintenance for the immune and endocannabinoid systems, while CV Acute delivers high intensity immune support when needed.”

CV Acute will be available at select retailers nationwide and through major e-commerce retailers by August 2020.